Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioXXmed AGFRA:T5O +5.19%38 Quick Ratio is 103.00 as of Dec. 2025, which is 363% above its 10-year median of 22.26. GuruFocus rates FRA:T5O with a GF Score™ of 38/100 and a GF Value™ of €10.79 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, bioXXmed AG ranks better than 99.65% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. bioXXmed AG's quick ratio for the quarter that ended in Dec. 2025 was 103.00.
bioXXmed AG has a quick ratio of 103.00. It generally indicates good short-term financial strength.
The historical rank and industry rank for bioXXmed AG's Quick Ratio or its related term are showing as below:
FRA:T5O'
s Quick Ratio Range Over the Past 10 Years
Min: 1.06 Med: 22.26 Max: 103
Current: 103
During the past 13 years, bioXXmed AG's highest Quick Ratio was 103.00. The lowest was 1.06. And the median was 22.26.
FRA:T5O's Quick Ratio is ranked better than 99.65% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs FRA:T5O: 103.00
bioXXmed AG (FRA:T5O) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
bioXXmed AG Quick Ratio Related Terms
bioXXmed AG Quick Ratio Historical Data
* Premium members only.
The historical data trend for bioXXmed AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:T5O vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, bioXXmed AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioXXmed AG Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, bioXXmed AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where bioXXmed AG's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
bioXXmed AG's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioXXmed AG (FRA:T5O) has a Quick Ratio of 103.00 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on bioXXmed AG and its competitors. This is 363% above median its historical median of 22.26. Over the past decade, bioXXmed AG's Quick Ratio has ranged from 1.06 to 103.00. According to the industry distribution chart, bioXXmed AG ranks #5 out of 1411 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is bioXXmed AG's Quick Ratio too high?
bioXXmed AG's current Quick Ratio of 103.00 is 363% above median its 10-year median of 22.26. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 103.00. The Biotechnology industry median Quick Ratio is 3.59. bioXXmed AG's value of 103.00 is 2769.1% above this industry median. Based on the distribution chart, bioXXmed AG ranks #5 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, bioXXmed AG has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, bioXXmed AG ranks #5 out of 1411 companies for Quick Ratio. This places bioXXmed AG in the top 0% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. bioXXmed AG's value of 103.00 is 2769.1% above this benchmark. Historically, bioXXmed AG's own Quick Ratio has ranged from 1.06 to 103.00 over the past decade. While the company's 10-year median is 22.26 vs. the industry median of 3.59, bioXXmed AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioXXmed AG's current Quick Ratio of 103.00 is 2769.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on bioXXmed AG and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioXXmed AG's current Quick Ratio is 103.00, which is 363% above median its own 10-year median of 22.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (FRA:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €10.79, compared to a current price of €0.81 — trading 92.5% below its estimated fair value. The current Quick Ratio is 103.00, which is 363% above median its 10-year median of 22.26 and 2769.1% above the Biotechnology industry median of 3.59. bioXXmed AG's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For bioXXmed AG (FRA:T5O), the current Quick Ratio is 103.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioXXmed AG (FRA:T5O) Overvalued in 2026?
Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued.
The current stock price of €0.81 is trading 92.5% below its estimated GF Value™ of €10.79.
GuruFocus considers bioXXmed AG to be Possible Value Trap.
Key valuation signals for FRA:T5O:
Quick Ratio: 103.00 (363% above median its 10-year median of 22.26)
GF Value™: €10.79 vs. price of €0.81 (92.5% below fair value)
Industry Position: 2769.1% above the Biotechnology median (#5 of 1411)
No single metric tells the full story. See the FRA:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
38GF Score
Get the complete analysis for FRA:T5O
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T5O has been successfully added to your 
